We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.30 | -0.66% | 45.00 | 44.50 | 45.50 | 45.25 | 44.25 | 45.25 | 2,895,504 | 16:28:25 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.26 | 127.63M |
From Apr 2019 to Apr 2024
TIDMAVCT
RNS Number : 3020J
Avacta Group PLC
29 March 2018
29 March 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Directorate Change
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, announces that Dr Michael Albin, one of the Group's Non-Executive Directors will be stepping down from the Board with effect from 30 March 2018.
Dr Alastair Smith, Group Chief Executive Officer, commented:
"I would like to thank Michael for his contribution to the Group over the last four years, his advice and support around the development of our Affimer technology has been invaluable. I am glad that Michael's association with Avacta will continue in an advisory capacity."
- Ends -
For further information from Avacta Group plc, please contact:
Hot Features
Premium
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207 220
Geoff Nash / Giles Rolls 0500
- Nominated Adviser www.finncap.com
Tim Redfern / Alice Lane
/ Nikita Jain - Corporate
Broking
Tel: +44 (0) 203 705
WG Partners 9318
Nigel Birks / Nigel Barnes Tel: +44 (0) 203 705
David Wilson / Claes Spang 9217
www.wgpartners.co.uk
Zyme Communications (Trade Tel: +44 (0)7787 502
and Regional Media) 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Tel: +44 (0)7764 947137
Media and IR) avacta@yellowjerseypr.com
Sarah Hollins
To register for Avacta news alerts by email go to www.avacta.com/investor-news-email-alerts
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFFEVTITFIT
(END) Dow Jones Newswires
March 29, 2018 02:02 ET (06:02 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
